Presentation is loading. Please wait.

Presentation is loading. Please wait.

Joint pain location and severity.

Published byKamila Pavlíková Modified over 5 years ago

Similar presentations

Presentation on theme: "Joint pain location and severity."— Presentation transcript:

1 Joint pain location and severity.
Joint pain location and severity. Reported answers to the following question: ‘how much pain did you have on average over the last month in mentioned body areas?’ Levels of pain ranging from no to severe, expressed as mean percentage of the left and right side of the body. Total group: ACPA and/or RF-positive individuals combined with seronegative individuals. FDR of patients with RA presented as comparison group. ACPA, anticitrullinated protein antibodies; FDR, first degree relatives; RA, rheumatoid arthritis; RF, rheumatoid factor. Marian H van Beers-Tas et al. RMD Open 2018;4:e000641 Copyright © BMJ Publishing Group & EULAR. All rights reserved.

Download ppt "Joint pain location and severity."

Similar presentations

Summary of TB cases across indications and trial periods

Summary of TB cases across indications and trial periods
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
Multivariable model of abatacept retention in biologic-naïve patients.

Multivariable model of abatacept retention in biologic-naïve patients.
Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.
(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Main fields of interest.

Main fields of interest.
Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.
Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.
Cells and mediators of the immune-inflammatory ‘cascade’ leading to overt clinical rheumatoid arthritis are described. Cells and mediators of the immune-inflammatory.

Cells and mediators of the immune-inflammatory ‘cascade’ leading to overt clinical rheumatoid arthritis are described. Cells and mediators of the immune-inflammatory.
Patient disposition through 48 weeks in RA-BEYOND

Patient disposition through 48 weeks in RA-BEYOND
Frequency of patients in flare at each time point over 3 months

Frequency of patients in flare at each time point over 3 months
Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.
P75NTR and disease severity (A) in persistent oligoarticular (n=29), extended oligoarticular (n=16) and polyarticular (n=13) patients p75NTR mRNA expression.

P75NTR and disease severity (A) in persistent oligoarticular (n=29), extended oligoarticular (n=16) and polyarticular (n=13) patients p75NTR mRNA expression.
The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.
Ratings of core domains stratified by stakeholder group in the second Delphi round. Ratings of core domains stratified by stakeholder group in the second.

Ratings of core domains stratified by stakeholder group in the second Delphi round. Ratings of core domains stratified by stakeholder group in the second.
Cumulative probability of time to achieve first sustained DAS28 (CRP) remission by conversion to ACPA seronegative status. Cumulative probability of time.

Cumulative probability of time to achieve first sustained DAS28 (CRP) remission by conversion to ACPA seronegative status. Cumulative probability of time.
(A) Reduction of circulating stromal cell-derived factor (SDF)-1 levels over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis.

(A) Reduction of circulating stromal cell-derived factor (SDF)-1 levels over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis.

Similar presentations

Ads by Google